Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report
The survey data reveal an increasing diagnostic effort for cardiac amyloidosis from 2021 to 2024, with a similar trend observed in all three countries. The average positivity rate in 2024 was almost 40% vs. about 33% in 2021. The results from 2021 to 2024 across all participants demonstrate improved pre-selection by the referring physicians but also increased awareness and improved training among nuclear medicine physicians.
Authors
- Ronny R. Buechel (ORCID: https://orcid.org/0000-0001-8064-8904)
- Oliver Lindner (ORCID: https://orcid.org/0000-0003-3777-0052)
- Jan Bucerius
- Thorsten Derlin (ORCID: https://orcid.org/0000-0002-8786-4105)
- B. Burchert
Institutions
- Medical University of Graz (AT)
- Heart and Diabetes Center North Rhine-Westphalia (DE)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1007/s00259-025-07601-8
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.81